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the risks. Ultimately, the decision to
continue or discontinue the use of a
medical device when localised skin
symptoms occur has to be made in
consultation with the patient.
JB reports personal fees from Abbott Diabetes Care,
AstraZeneca, Insulet Corporation, Integrity
Applications, Lilly, NovoNordisk, and Sanofi. RA and
PG-D declare no competing interests. JK is on the
advisory board for Abbott Diabetes Care, and
reports personal fees from Abbott Diabetes Care,
Lilly, Novo Nordisk, Berlin Chemie, Medtronic,
Sanofi, MSD, and AstraZeneca. RW reports personal
fees from Abbott.

*Jan Bolinder, Ramiro Antuna,
Petronella Geelhoed-Duijvestijn,
Jens Kröger, Raimund Weitgasser
jan.bolinder@ki.se
Department of Medicine, Karolinska University
Hospital Huddinge, Karolinska Institute,
Stockholm 141 86, Sweden (JB); Clinidiabet,
Corrida, Gijón, Spain (RA); Department of Internal
Medicine, Medical Center Haaglanden, The Hague,
Netherlands (PG-D); Centre for Diabetology
Hamburg Bergedorf, Hamburg, Germany (JK);
Department of Internal Medicine,
Wehrle-Diakonissen Hospital Salzburg, Salzburg,
Austria (RW); and Paracelsus Medical University,
Salzburg, Austria (RW)
1

2

3

4

5

Bolinder J, Antuna R, Geelhoed-Duijvestijn P,
Kröger J, Weitgasser R. Novel glucose-sensing
technology and hypoglycaemia in type 1
diabetes: a multicentre, non-masked,
randomised controlled trial. Lancet 2016;
388: 2254–63.
Ramchandani N, Arya S, Ten S, Bhandari S.
Real-life utilization of real-time continuous
glucose monitoring: the complete picture.
J Diabetes Sci Technol 2011; 5: 860–70.
Wong JC, Foster NC, Maahs DM, et al, for the
T1D Exchange Clinic Network. Real-time
continuous glucose monitoring among
participants in the T1D exchange registry.
Diabetes Care 2014; 37: 2702–09.
Englert K, Ruedy K, Coffey J, Caswell K,
Steffen A, Levandoski L, for the Diabetes
Research in Children (DirecNet) Study Group.
Skin and adhesive issues with continuous
glucose monitors: a sticky situation.
J Diabetes Sci Technol 2014; 8: 745–51.
Heinemann L, Kamann S. Adhesives used for
diabetes medical devices: a neglected risk with
serious consequences? J Diabetes Sci Technol 2016;
10: 1211–15.

Physician burnout is
better conceptualised as
depression
Ronald Epstein and Michael Privitera
(Nov 5, p 2216)1 reported that burnout
affects more than half of practising

physicians. The authors additionally
warned against confusing burnout
with depression. We are concerned
with the validity of these conclusions.
First, there is now robust evidence
that burnout is a depressive condition.2,3
The misunderstanding surrounding
burnout–depression overlap might
reflect both a neglect of the stress–
depression association and a difficulty
coordinating dimensional and
categorical approaches to depression in
burnout research. The issue is not about
interchanging one term with the other.
By cultivating the idea that burnout
is not a depressive condition, despite
evidence to the contrary, investigators
inhibit themselves from exploiting the
accumulated knowledge on treating and
preventing (job-induced) depression
when helping sufferers of burnout.
Second, the published estimates of
burnout’s prevalence rely on clinically
groundless criteria, cobbled together
without any rationale.4 In one study,5
depending on how burnout was
identified, the prevalence of burnout
went from 69% to 10%, showing
a worrying malleability. Because
estimates of prevalence of burnout
do not have a nosological frame and
are adjustable at convenience, they
can be easily challenged by anyone
willing to discourage public health
initiatives intended to enhance working
conditions and alleviate job stress.
Recognising burnout–depression
overlap would help resolve the problem.
By contrast to burnout, depression, in
its different forms, is diagnosable in a
consensual and clinically valid way.
Promoting occupational health is a
difficult job. The major organisational
changes recommended by Epstein and
Privitera1 are unlikely to be implemented
without resistance. Switching from a
the construct of burnout to depression
would strengthen research validity and
public health decision-making authority.
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which might be contributing factors to
adverse events.4,5 Sensor-wear-related
symptoms were recorded as adverse
events in the IMPACT trial if the effects
were severe and lasted for more than
7 days, or if the patient required
prescription medication for the event
to resolve. Adverse event severities
were recorded on the basis of a healthcare professionals assessment of mild,
moderate, or severe events.
According to the study protocol,
individuals with known sensitivity
to medical-grade adhesives were
excluded from participation. However,
we reasonably expected that a few
participants might have been unaware
of their sensitivity until they had
exposure to the product for longer
than a few days. For participants
with adverse events involving skin
symptoms during this trial, symptoms
(including severe) were resolved by use
of barrier products (eg, Cavilon spray)
or drug therapy (eg, zinc ointment,
Fenistil gel, or hydrocortisone
cream) as prescribed, or simply by
relocating the device to another area
of the skin such that the effects were
maintained at a tolerable, background
level. In other cases, although the
adverse events were generally mild
or moderate, the longevity of the
symptoms, despite use of treatment,
contributed to the participant’s
decision to withdraw from the trial.
None of the participants withdrew
because of health-care professional
advice to stop wearing the sensor.
Since completion of the IMPACT
trial, minor design changes have been
made to FreeStyle Libre. These changes
are expected to improve breathability
of the skin that is in contact with the
sensor and to facilitate the exclusion
of moisture between the sensor–skin
interface.
We conclude that although some
individuals might be intolerant to using
devices with medical-grade adhesive,
others might have manageable skin
symptoms from sensor wear. Overall,
we believe that the benefits of using
such a system generally outweigh
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We agree with Renzo Bianchi and
colleagues that the public health
significance of job-related distress
is large—and costly in both human
and financial terms1—and that the
variability of definitions and thresholds
for burnout in the literature have been
problematic. West and colleagues’
review in The Lancet2 addressed that
issue partly by using one definition of
burnout (high emotional exhaustion or
depersonalisation) and also supplying
data on individual domains and
numerical Maslach burnout inventory
scale scores. Importantly, these scores,
taken as continuous or dichotomous
variables, have been clearly linked with
clinically relevant outcomes and are
responsive to both institutional and
individual interventions. Although
there is still a need for conceptual
clarification now that physician
distress is finally recognised as a serious
problem, discarding the construct of
burnout altogether seems unwarranted.
Recognition of major depression
is important. We do not agree,
however, that there is robust evidence
that burnout is merely depression.3
Although there is substantial overlap
between the two conditions, and
physicians with the highest amount
of burnout are more likely to develop

major depression, workers often
have one without the other. Maslach
and colleagues, addressed this issue
early in development of the burnout
construct and assessment scale4 and
again recently.1 Appropriately, burnout
is conceptualised as a breakdown in
the relationship between people and
their work. That burnout has worsened
acutely in the context of radical changes
in the nature of clinical work—electronic
health records that reduce face-to-face
time and documentation mandates
that have exponentially increased the
burden of meaningless tasks—speaks
against a purely individual syndrome.
Pragmatically speaking, considering
burnout solely as a mental illness of
individual workers rather than workrelated distress would be disastrous in
the US context and perhaps elsewhere.
Many US institutions and medical
boards require that physicians report
any history of mental illness when
applying for a medical licence and
hospital privileges, an unfortunate
reality. Physicians will be more willing
to accept that they are burned out and
seek help if they feel that they will not
be stigmatised for what they see as a
systemic or institutional problem. In
March, 2016, Vivek Murthy, the US
Surgeon General, declared that burnout
among health-care workers was one of
the two most pressing health problems
in the nation to be addressed during the
subsequent year. It is our hope that we
will continue to clarify the conceptual
and measurement issues while moving
forward quickly to alleviate a pressing
national—and global—problem.
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